Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 148 of the 151 references it cites were found in a registry or an index; 54 of the 207 sources its claims cite were checked for support.

Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.

Open access
Cumming, Paul, Scheidegger, Milan, Dornbierer, Dario, Palner, Mikael, Quednow, Boris B., Martin-Soelch, Chantal · 2021 · Molecules

Abstract

Hallucinogens are a loosely defined group of compounds including LSD, N,N-dimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), which can evoke intense visual and emotional experiences. We are witnessing a renaissance of research interest in hallucinogens, driven by increasing awareness of their psychotherapeutic potential. As such, we now present a narrative review of the literature on hallucinogen binding in vitro and ex vivo, and the various molecular imaging studies with positron emission tomography (PET) or single photon emission computer tomography (SPECT). In general, molecular imaging can depict the uptake and binding distribution of labelled hallucinogenic compounds or their congeners in the brain, as was shown in an early PET study with N1-([11C]-methyl)-2-bromo-LSD ([11C]-MBL); displacement with the non-radioactive competitor ketanserin confirmed that the majority of [11C]-MBL specific binding was to serotonin 5-HT2A receptors. However, interactions at serotonin 5HT1A and other classes of receptors and pleotropic effects on second messenger pathways may contribute to the particular experiential phenomenologies of LSD and other hallucinogenic compounds. Other salient aspects of hallucinogen action include permeability to the blood–brain barrier, the rates of metabolism and elimination, and the formation of active metabolites. Despite the maturation of radiochemistry and molecular imaging in recent years, there has been only a handful of PET or SPECT studies of radiolabeled hallucinogens, most recently using the 5-HT2A/2C agonist N-(2[11CH3O]-methoxybenzyl)-2,5-dimethoxy- 4-bromophenethylamine ([11C]Cimbi-36). In addition to PET studies of target engagement at neuroreceptors and transporters, there is a small number of studies on the effects of hallucinogenic compounds on cerebral perfusion ([15O]-water) or metabolism ([18F]-fluorodeoxyglucose/FDG). There remains considerable scope for basic imaging research on the sites of interaction of hallucinogens and their cerebrometabolic effects; we expect that hybrid imaging with PET in conjunction with functional magnetic resonance imaging (fMRI) should provide especially useful for the next phase of this research.

Overview

CoChat Summary

TL;DR

This is a narrative review of in vitro, ex vivo, PET/SPECT, and perfusion/metabolic imaging studies of hallucinogens, with a particular focus on serotonin receptor pharmacology and brain target engagement. Across the literature summarized, hallucinogens are presented as chiefly 5-HT2A agonists, but with important contributions from other receptors, metabolism, and flow-metabolism coupling to their effects.

Key findings

  • The review states that hallucinogens generally share agonism at 5-HT2A sites, but many also show high affinity at 5HT2C and 5HT1A receptors; for example, LSD had Ki values of 3 nM at 5HT1A, 4 nM at 5HT2A, and 15 nM at 5HT2C sites, while psilocin had Ki values of 49 nM at 5HT2A, 94 nM at 5HT2C, and 123 nM at 5HT1A sites.
  • In human PET work, psilocybin/psilocin produced substantial 5HT2A occupancy: Madsen et al. reported occupancy as high as 76% at plasma psilocin around 100 nM, and Hasler et al. reported widespread 50% decreases in [18F]-altanserin uptake after 20 mg psilocybin in 11 healthy young male subjects.
  • Imaging findings summarized include both increased and decreased cerebral activity depending on tracer and modality: psilocybin increased CMRglc by up to +25% in frontal cortex, anterior cingulate, and medial temporal cortex in one FDG PET study (n = 10), while ASL/SPECT studies often found reduced perfusion in widespread regions after psilocybin or mescaline.
  • The review notes that radiolabeled hallucinogen studies are still sparse despite modern radiochemistry; it specifically highlights early [11C]-MBL PET showing cortical binding displaced by ketanserin, and says there remains “considerable scope” for further PET/SPECT and hybrid PET-fMRI research.

Methods

  • Narrative review of published literature on hallucinogen binding in vitro and ex vivo, plus molecular imaging studies using PET and SPECT; the article also discusses a smaller number of studies of cerebral perfusion and metabolism.
  • Evidence base spans animals and humans, including rats, mice, pigs, baboons, rabbits, monkeys, and healthy volunteers, as well as a clinical Ayahuasca study in patients with recurrent major depressive disorder.
  • Main analyses discussed include receptor-binding displacement/affinity studies, autoradiography, PET/SPECT tracer studies, competition paradigms (e.g., [11C]-raclopride, [18F]-altanserin, [11C]-Cimbi-36), and FDG/ASL perfusion imaging.

Limitations

  • The paper explicitly states that the molecular imaging literature on hallucinogens is “rather sparse,” with only a handful of PET/SPECT studies and some well-known hallucinogens “entirely uninvestigated” by molecular imaging.
  • Several findings are presented as interpretive or tentative, including possible confounding by anesthesia, metabolite effects, or drug mis-injection in animal imaging studies; these caveats are stated in the text.
  • By its own framing, this is a narrative review rather than a systematic review or meta-analysis; that limits the ability to draw pooled quantitative conclusions from the evidence presented.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/molecules26092451

Cites

148 of 148 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Chemical structures of LSD and some classic hallucinogenic compounds—(*) indicates chiral centers.
Figure 1 Chemical structures of LSD and some classic hallucinogenic compounds—(*) indicates chiral centers.CC BY · PubMed Central
Figure 2 Structure of selected ibogaine and lisuride derivatives.
Figure 2 Structure of selected ibogaine and lisuride derivatives.CC BY · PubMed Central
Figure 3 Structures of some dimethoxyamphetamines and serotonin receptor antagonists.
Figure 3 Structures of some dimethoxyamphetamines and serotonin receptor antagonists.CC BY · PubMed Central
Figure 4 [11C]-Cimbi-36 (38) activity summed over the 45 min scan time in rat brain (right) overlaid on an MR template image in the horizontal plane (left). High activity in cortical regions, especially mPFC, moderate activity in striatal and hippocampal regions and low binding in cerebellum.
Figure 4 [11C]-Cimbi-36 (38) activity summed over the 45 min scan time in rat brain (right) overlaid on an MR template image in the horizontal plane (left). High activity in cortical regions, especially mPFC, moderate activity in striatal and hippocampal regions and low binding in cerebellum.CC BY · PubMed Central
Figure 5 Structures of serotonin and some indole alkaloids.
Figure 5 Structures of serotonin and some indole alkaloids.CC BY · PubMed Central
Figure 6 Inverse Correlation of 5D-ASC Global Scale scores and [18F]-altanserin (39) apparent distribution volume [DV’]. Results of a voxel based correlation analysis (Δ 5D-ASC global vs. ΔDV’, threshold p < 0.005, uncorrected) using Statistical Parametric Mapping [105]. Reproduced with permission.
Figure 6 Inverse Correlation of 5D-ASC Global Scale scores and [18F]-altanserin (39) apparent distribution volume [DV’]. Results of a voxel based correlation analysis (Δ 5D-ASC global vs. ΔDV’, threshold p < 0.005, uncorrected) using Statistical Parametric Mapping [105]. Reproduced with permission.CC BY · PubMed Central
Figure 7 Mean parametric maps of the total distribution volume of 5-[11C]-MeO-DMT (47) in brain of groups of three pigs at baseline and after treatment with the irreversible MAO A/B inhibitor, pargyline. There was no evidence of potentiation of the tracer uptake by blockade of MAO, nor was the binding in ventral striatum displaceable in studies with ketanserin (7) pretreatment (Jensen and Cumming, unpublished observations).
Figure 7 Mean parametric maps of the total distribution volume of 5-[11C]-MeO-DMT (47) in brain of groups of three pigs at baseline and after treatment with the irreversible MAO A/B inhibitor, pargyline. There was no evidence of potentiation of the tracer uptake by blockade of MAO, nor was the binding in ventral striatum displaceable in studies with ketanserin (7) pretreatment (Jensen and Cumming, unpublished observations).CC BY · PubMed Central

Verification

Claims the paper makes

47 Valid · 5 Not valid · 140 Not checked · 53 Own results and interpretations

129 more claims · 24 with their cited sources checked

Create a free account to see all 245 claims and to verify the 22 references still open.

See all claims — free account
  • It may state two separate claims as one. 104
  • Probably not a substantial claim. 11
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 151 references

Research works printed but not linked: 2

  1. Shulgin, A.T., and Shulgin, A. (1997). THIKAL, The Continuation, Transform Press.
  2. Hasler, 2009, Role of prefrontal serotonin-2A receptors in self experience during pilocybin-indiced altered states, Neuropsychobiology, 59, 60

Cited by

See all 44

Metadata

Authors
Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C.
Affiliations
  • Queensland University of Technology (AU)
  • University of Zurich (CH)
  • University of Southern Denmark (DK)
  • Department of Psychology, University of Fribourg, CH-1700 Fribourg, Switzerland
Corresponding author
Cumming, Paul
Venue
Molecules
Publisher
MDPI AG
Published
2021-04-22
Volume
26
Issue
9
Pages
2451
ISSN
1420-3049 (ISSN-L)
OpenAlex
W3153638782
Cited by
43
References
151
Citations by year
2026: 2 · 2025: 7 · 2024: 11 · 2023: 9 · 2022: 12 · 2021: 2
FWCI
1.16
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • QUT ePrints (Queensland University of Technology) (submittedVersion, cc-by)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • ETH Zürich Research Collection (cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
Keywords
hallucinogens, psychedelics, 5-HT2A receptor, 5-HT1A receptor, PET radiotracer, blood-brain barrier permeability, cerebral perfusion, brain glucose metabolism
MeSH terms
Clinical Studies as Topic, Animals, Carrier Proteins, Cerebrovascular Circulation, Drug Evaluation, Preclinical, Energy Metabolism, Hallucinogens, Humans, Image Processing, Computer-Assisted, Protein Binding, Molecular Structure, Biomarkers, Tomography, Emission-Computed, Single-Photon, Drug Monitoring, Positron-Emission Tomography, Molecular Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. https://app.cochat.ai/papers/10.3390/molecules26092451
The paper
Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C. (2021). Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. Molecules. https://doi.org/10.3390/molecules26092451

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.